Abstract
Whereas patients with multiple myeloma continue to relapse after autologous transplantation and are unlikely to be cured, the probability of progression is less after allogeneic transplantation and a proportion of patients may be cured. This is attributable to an immunologically mediated graft-versus-myeloma (GVM) effect which is akin to the well-known graft-versus-leukemia effect. The available clinical and experimental evidence strongly support the existence of GVM, but it is not known whether GVM is separable from graft-versus-host disease (GVHD) in practice. The best way to exploit GVM reactions is unclear, and the morbidity and mortality associated with GVHD undermine long-term survival. There is usually a time lag of a few weeks between immune intervention and disease response. There is a propensity for extramedullary disease recurrence in patients whose marrow disease is controlled with immunologic manipulation. Exploration of GVM outside conventional allogeneic transplantation or after autologous transplantation is necessary to increase the number of patients likely to benefit from this phenomenon and to make it safer. This article reviews the currently available literature on the subject.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mehta, J., Singhal, S. Graft-versus-myeloma. Bone Marrow Transplant 22, 835–843 (1998). https://doi.org/10.1038/sj.bmt.1701459
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701459
Keywords
This article is cited by
-
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
Bone Marrow Transplantation (2008)
-
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years
Bone Marrow Transplantation (2007)
-
Lenalidomide in Myeloma
Current Treatment Options in Oncology (2007)
-
The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma
Leukemia (2006)
-
Outcome of unrelated transplants in patients with multiple myeloma
Bone Marrow Transplantation (2005)